A Phase 2 interventional study of Sotatercept in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Recruiting at 3 sites in Japan. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 18th largest by planned enrollment, is one of 4 that started in 2026, is one of 7 in phase 2, and was the 17th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in India
Ages 18+
Kazuya Hosokawa · Sites in Japan
Ages 18+
Amsterdam UMC, location VUmc · Sites in Netherlands
Ages 18–70
Merck Sharp & Dohme LLC · Sites in United States, Australia, Colombia and 9 more countries
Ages 1–17
Oregon Health and Science University · Sites in United States
Ages 18+
By country, each count listing its studies:
sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 6 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 44 across the 18 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc: 3 open now, 5 under way, 1 of them phase 3. Of 12 finished, 11 (92%) have results posted.
Among the 17 studies in Pulmonary Arterial Hypertension by Merck & Co., Inc, this one is the 17th largest by planned enrollment, is one of 2 that started in 2026, is one of 6 in phase 2, and was the 17th registered.
Merck & Co., Inc’s Pulmonary Arterial Hypertension studies by the year they started, since 2013.
1 of the studies testing sotatercept in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07356778Kazuya HosokawaA Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy | 2027-08-31 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, from their registry updates:
Among Merck & Co., Inc’s 17 in Pulmonary Arterial Hypertension:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment. Researchers also want to learn what happens to it in a person's body over time and whether it lowers resistance in blood vessels in the lungs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive sotatercept by subcutaneous injection every 3 weeks (Q3W) for up to approximately 24 weeks while continuing standard-of-care background therapy for PAH. Participants start at a dose of 0.3 mg/kg Q3W, and may titrate up to the target dose of 0.7 mg/kg SC injection Q3W starting at Week 6 based on protocol-defined dose-escalation guidance. After Week 24, participants who meet certain requirements may choose to continue receiving sotatercept for up to 58 months.
Biological: Sotatercept
Sotatercept subcutaneous injection every 3 weeks
Also known as: MK-7962, ACE-011, ActRIIA-IgG1Fc, WINREVAIR®
Number of Participants With One or More Adverse Events
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 24 weeks
Number of Participants Who Discontinue Study Intervention Due to an Adverse Event
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 24 weeks
Laboratory Parameter (Hematology): Concentration of Hemoglobin
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The concentration of hemoglobin will be presented.
Time frame: Up to approximately 24 weeks
Laboratory Parameter (Hematology): Hematocrit
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The hematocrit will be presented.
Time frame: Up to approximately 24 weeks
Laboratory Parameter (Hematology): Red Blood Cell (RBC) Count
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The RBC count will be presented.
Time frame: Up to approximately 24 weeks
Laboratory Parameter (Hematology): Reticulocyte Count
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The reticulocyte count will be presented.
Time frame: Up to approximately 24 weeks
Laboratory Parameter (Hematology): Platelet Count
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The platelet count will be presented.
Time frame: Up to approximately 24 weeks
Blood Pressure (BP)
BP will be assessed while the participant was seated after a period of rest in a quiet setting with no distractions (eg, television and cell phones).
Time frame: Up to approximately 24 weeks
Number of Participants with Detectable Anti-Drug Antibodies (ADAs)
Blood samples will be collected to assess antidrug antibodies to sotatercept. The number of participants with detectable ADAs at any time during the study will be presented.
Time frame: Up to approximately 24 weeks
Number of Participants with Detectable Neutralizing Antibodies to Sotatercept
Neutralizing antibody analysis will be performed on blood samples for participants who are confirmed as antidrug antibody-positive. The number of participants with detectable neutralizing antibodies at any time during the study will be presented.
Time frame: Up to approximately 24 weeks
Serum Trough Concentration (Ctrough) of Sotatercept
Serum samples collected predose will be used to determine serum trough concentration (Ctrough) of sotatercept.
Time frame: At designated time points and up to approximately 24 weeks
Change From Baseline in Pulmonary Vascular Resistance Index (PVRI)
The change from baseline in PVRI will be presented.
Time frame: Baseline and Week 24
Mean Change from Baseline in 6-Minute Walk Distance (6MWD)
6MWD will be assessed using the 6-minute walk test (6MWT).
Time frame: Baseline and Week 24
Mean Change from Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP)
The change from baseline in plasma NT-proBNP levels will be reported.
Time frame: Baseline and Week 24
Percentage of Participants Who Either Improved or Maintained Their World Health Organization Functional Class (WHO FC)
The severity of an individual's PAH symptoms will be graded using the WHO FC system. WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO FC will be classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC.
Time frame: Baseline and Week 24
Number of Participants With One or More Adverse Events
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From Week 24 up to approximately 58 months
Number of Participants Who Discontinue Study Intervention Due to an Adverse Event
An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From Week 24 up to approximately 58 months
Laboratory Parameter (Hematology): Concentration of Hemoglobin
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The concentration of hemoglobin will be presented.
Time frame: From Week 24 up to approximately 58 months
Laboratory Parameter (Hematology): Hematocrit
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The hematocrit will be presented.
Time frame: From Week 24 up to approximately 58 months
Laboratory Parameter (Hematology): Red Blood Cell (RBC) Count
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The RBC count will be presented.
Time frame: From Week 24 up to approximately 58 months
Laboratory Parameter (Hematology): Reticulocyte Count
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The reticulocyte count will be presented.
Time frame: From Week 24 up to approximately 58 months
Laboratory Parameter (Hematology): Platelet Count
Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The platelet count will be presented.
Time frame: From Week 24 up to approximately 58 months
Blood Pressure (BP)
BP will be assessed while the participant was seated after a period of rest in a quiet setting with no distractions (eg, television and cell phones).
Time frame: From Week 24 up to approximately 58 months
Number of Participants with Detectable ADAs
Blood samples will be collected to assess antidrug antibodies to sotatercept. The number of participants with detectable ADAs at any time during the study will be presented.
Time frame: From Week 24 up to approximately 58 months
Number of Participants with Detectable Neutralizing Antibodies to Sotatercept
Neutralizing antibody analysis will be performed on blood samples for participants who are confirmed as ADA-positive. The number of participants with detectable neutralizing antibodies at any time during the study will be presented.
Time frame: From Week 24 up to approximately 58 months
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started Sep 2026 (actual). Primary completion is estimated for May 2029, 32 months after the start.
Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 32 months is close to that.
Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept
Pulmonary Arterial Hypertension →